To view this email as a web page, click here

Today's Rundown

Featured Story

The $38B pie: Pfizer, Moderna COVID-19 vaccines set for lion's share of 2021 sales

With the first COVID-19 vaccinations expected to start in the coming weeks, 2021 is shaping up to be quite a year for the companies leading the vaccine race. Specifically, there's tens of billions on the line, Bernstein analysts wrote—and the first-to-market shots will reap more than half of it.

read more

Top Stories

CDC panel recommends healthcare workers, long-term care residents and staff be first to get COVID-19 vaccine

A Centers for Disease Control and Prevention panel has recommended that healthcare workers and residents and staff of long-term care facilities be the first to get a COVID-19 vaccine when it is approved.

read more

Roche nets FDA authorization for quantitative COVID-19 antibody test

Roche has received authorization from the FDA for a more accurate COVID-19 blood test capable of measuring the levels of specific antibodies that target the coronavirus’s cell-unlocking spike protein.

read more

Sponsored: Predicting Landfall: A Dynamic Control Room for Taking on the COVID-19 Landscape

When it comes to COVID-19 commercialization, multiple disrupters are likely to impact an asset’s trajectory. Gain the real-time perspective needed to pivot fast in an ever changing environment.

read more

Operation Warp Speed pushing to vaccinate 100M against COVID-19 by end of February

Operation Warp Speed rolled out an ambitious goal to vaccinate 100 million people against COVID-19 by the end of February as the first vaccine is expected to get approval soon.

read more

CMS looks to permanently expand telehealth services

CMS added more telehealth services that can be reimbursed by Medicare as the agency lays the groundwork to keep telehealth flexibility once the pandemic ends.

read more

Healthcare roundup: Ballad Health pauses elective surgeries as COVID-19 cases mount

Follow along with the latest COVID-19 news straight from the Fierce Healthcare team.

read more

Biopharma roundup: Merck divests stake in Moderna; Pfizer poised for $14B-plus in 2021 vaccine sales: analysts

Pfizer is set to pull in $14.3 billion in COVID vaccine sales next year, Bernstein analysts predict. Merck divested its stake in Moderna, resulting in "a small fourth quarter gain." The U.S. aims to vaccinate 100 million people by February. And Roche won FDA authorization for a quantitative antibody test.

read more

Merck cashes in on Moderna COVID-19 vaccine enthusiasm with sale of equity stake

Merck made a $50 million equity investment in Moderna back in 2015 and invested $125 million in the mRNA startup three years later. Their research pact is focused on mRNA vaccines for cancer, but now that Moderna is nearing the finish line on its COVID-19 vaccine, Merck is cashing in on what turned out to be a prescient bet.

read more